ROCK Inhibition and Cytoskeletal Dynamics for Alzheimer's Disease

Overview

Rho-associated coiled-coil containing protein kinase (ROCK) inhibition represents a promising therapeutic approach for Alzheimer's disease that targets multiple disease mechanisms: neuroprotection, actin cytoskeleton modulation, dendritic spine remodeling, and cerebral blood flow enhancement. This page tracks companies developing ROCK inhibitors for AD.

Mechanism of Action

Key Therapeutic Mechanisms

Overview

Rho-associated coiled-coil containing protein kinase (ROCK) inhibition represents a promising therapeutic approach for Alzheimer's disease that targets multiple disease mechanisms: neuroprotection, actin cytoskeleton modulation, dendritic spine remodeling, and cerebral blood flow enhancement. This page tracks companies developing ROCK inhibitors for AD.

Mechanism of Action

Key Therapeutic Mechanisms

ROCK Isoforms

| Isoform | Expression | Therapeutic Target |
|---------|-------------|-------------------|
| ROCK1 | Ubiquitous | Cytoskeleton, inflammation |
| ROCK2 | Neurons, smooth muscle | Synaptic plasticity, vasodilation |

Companies Developing ROCK Inhibitors for AD

Clinical Stage Programs

| Company | Compound | Stage | Mechanism |
|---------|----------|-------|-----------|
| Eidogen/Ascend | Fasudil | Preclinical | Broad ROCK inhibition |
| Kowa | KD-1 | Preclinical | ROCK1/2 selective |
| Wyeth | Wf-536 | Discontinued | ROCK inhibition |
| Santen | Y-39983 | Preclinical | Ocular/CNS |
| Schering | SAR407899 | Preclinical | Vascular effects |
| Kissei | RKI-983 | Preclinical | Neuroprotection |
| Denali | DNL921 | Discovery | Brain-penetrant |
| Cerevel | CVL-231 | Phase 1 | CNS-selective |

Preclinical and Discovery Programs

Fasudil (Eidogen/Ascend):

• First ROCK inhibitor approved in Japan (cerebral vasospasm)
• Being reformulated for CNS delivery
• Evidence in AD mouse models: improves cognition, reduces Aβ

• ROCK program: DNL921
• Brain-penetrant ROCK inhibitor
• Focus on combination with other mechanisms
• Indication: Alzheimer's disease (preclinical)

• CVL-231: CNS-selective ROCK inhibitor
• Phase 1 studies in healthy volunteers
• Potential for AD treatment
• Also: CVN424 (D1/D5 partial agonist with D3 activity)

• GMP-101: ROCK2-selective inhibitor
• Stage: Discovery
• Focus: Neuroprotection

• NIR-002: Pan-ROCK inhibitor
• Stage: Preclinical
• Focus: Cerebral blood flow

Clinical Evidence

Preclinical Data

• AD models: ROCK inhibitors reduce Aβ toxicity in neurons
• Memory improvement: Enhanced spatial memory in Morris water maze
• Synaptic markers: Increased synaptophysin, PSD95 expression
• Blood flow: Improved cerebral blood flow in AD models

Challenges

Comparison with Other AD Approaches

| Approach | Target | Stage | Advantage |
|----------|--------|-------|-----------|
| ROCK inhibitors | Cytoskeleton, blood flow | Preclinical | Multi-target |
| Anti-amyloid | Aβ plaques | Approved | Disease-modifying |
| Tau immunotherapy | Tau tangles | Phase 3 | Disease-modifying |
| BACE inhibitors | Aβ production | Halted | Validated target |

Research Directions

Emerging Strategies

Cross-References

Related therapeutics:

• [Fasudil](/therapeutics/fasudil-parkinsons)
• [ROCK Signaling Pathway](/mechanisms/rock-signaling-neurodegeneration)

• [Cytoskeletal Dynamics](/mechanisms/cytoskeletal-dynamics-neurodegeneration)
• [Cerebral Blood Flow](/mechanisms/neurovascular-coupling)

References

Pathway Diagram

The following diagram shows the key molecular relationships involving ROCK Inhibition and Cytoskeletal Dynamics for Alzheimer's Disease discovered through SciDEX knowledge graph analysis: